Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2018 December;62(4) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2018 December;62(4):445-52

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

ORIGINAL ARTICLE   

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2018 December;62(4):445-52

DOI: 10.23736/S1824-4785.16.02862-4

Copyright © 2016 EDIZIONI MINERVA MEDICA

language: English

Clinical value of intratumoral metabolic heterogeneity in [18F]FDG PET/CT for prediction of recurrence in patients with locally advanced colorectal cancer

Yeon-Hee HAN, Hwan-Jeong JEONG, Myung-Hee SOHN, Seok T. LIM

Department of Nuclear Medicine, Molecular Imaging and Therapeutic Medicine Research Center, Chonbuk National University Hospital, Jeonju, South Korea


PDF


BACKGROUND: The aim of this study was to find a reliable predictor of recurrence in patients with locally advanced colorectal cancer.
METHODS: We enrolled 96 patients for this retrospective study. We investigated metabolic (SUVmax, metabolic tumor volume, total lesion glycolysis, and heterogeneity), clinical (age, sex, stage, and CEA level) and pathologic (Ki-67, p53, CD31, COX-2, E-cadherin and EGFR) parameters. The coefficient of variation (COV) was chosen to assess heterogeneity of [18F]FDG uptake by dividing the standard deviation of the SUV by SUVmean. Recurrence-free survival was compared with each metabolic, clinical and pathologic parameters by using univariate and multivariate survival analysis.
RESULTS: Among 96 patients, 19 patients (19.8%) showed disease recurrence. In the ROC analysis, the optimal cutoff values of SUVmax, metabolic tumor volume (cm3), total lesion glycolysis (cm3), and metabolic heterogeneity were determined as 17.6, 10.05, 232.46, and 0.48, respectively. In univariate analysis, probability of recurrence was statistically increased in those with metabolic tumor volume >10.05 (P=0.045), and those with metabolic heterogeneity >0.48 (P=0.031). In multivariate analysis, metabolic heterogeneity was the only independent prognostic factor (HR 4.56, 95% CI 1.57-13.23, P=0.006).
CONCLUSIONS: Intratumoral metabolic heterogeneity assessed by COV is a reliable predictive factor for disease recurrence in patients with locally advanced colorectal cancer. Therefore, its application could be an important step for personalized management of colorectal cancer.


KEY WORDS: Colorectal neoplasms - Recurrence - Prognosis - Fluorodeoxyglucose F18 - Tomography, X-ray computed - Positron emission tomography computed tomography

top of page